S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer (SOPP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01671449 |
Recruitment Status :
Completed
First Posted : August 23, 2012
Last Update Posted : November 30, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Gastric Cancer | Drug: S-1 Drug: Cisplatin Drug: Oxaliplatin | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 338 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer |
Study Start Date : | December 2012 |
Actual Primary Completion Date : | October 2014 |
Actual Study Completion Date : | October 2015 |
Arm | Intervention/treatment |
---|---|
Active Comparator: S-1 plus Cisplatin
|
Drug: S-1
S-1 : 40 mg/m2, twice daily, Day 1-14
Other Name: TS-1 Drug: Cisplatin 60 mg/m2/day Day 1 |
Experimental: S-1 plus Oxaliplatin
|
Drug: S-1
S-1 : 40 mg/m2, twice daily, Day 1-14
Other Name: TS-1 Drug: Oxaliplatin 130 mg/m2/day Day 1
Other Name: Pleoxin |
- Progression-free survival [ Time Frame: From date of randomization to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years ]The primary endpoint of this study is progression-free survival. This is defined as the time from randomization to disease progression or death due to any cause.
- Overall survival [ Time Frame: From date of randomization to death from any cause, assessed up to 3 years ]Overall survival is defined as the time from randomization to death due to any cause.
- Response rate [ Time Frame: Every 6 weeks ]Response assessment will be performed according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 every 2 cycles (6 weeks) of treatment.
- Quality of life [ Time Frame: Every 6 weeks ]Quality of life of patient will be evaluated using EUROQOL(EQ-5D). Evaluation of quality of life will be performed every 2 cycles (6 weeks) from baseline to the end of treatment.
- Number of Adverse Events [ Time Frame: Every 3 weeks ]Monitoring for safety and toxicity will be performed every cycle (3 weeks) of chemotherapy and whenever patients have problems.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Written informed consent before the enrollment
- Age ≥18 years old
- Histologically/cytologically confirmed recurrent or metastatic gastric or esophagogastric junctional adenocarcinoma
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Patients able to swallow food and drugs
- At least one measurable or evaluable lesion according to RECIST criteria version 1.1
-
Adequate bone, hepatic, and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to first administration of study drugs
- Absolute neutrophil count (ANC) ≥ 1,500/ uL, platelet ≥ 100,000/ uL, haemoglobin (Hb) ≥ 9.0 g/dl,
- Serum creatinine ≤ 1.5 mg/dL (If serum creatinine is greater than 1.5 mg/dL, creatinine clearance [Ccr] should be 60 mL/min or greater. Ccr is calculated by Cockcroft-Gault formula or 24hr urine collection)
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN), AST/ALT levels ≤ 3.0 x ULN (AST/ALT levels ≤ 5.0 x ULN for patients with liver involvement of their cancer)
- In patients who received adjuvant or neoadjuvant chemotherapy, completion of systemic chemotherapy 6 months before the study enrollment, and no previous administration of platinum derivatives
- Estimated life expectancy of more than 3 months
Exclusion Criteria:
- Other histologic types than adenocarcinoma
- Recurrence within 24 weeks following completion of adjuvant chemotherapy
- R1 gastrectomy (i.e., microscopic residual disease)
- History of another malignancy within the last five years from the day of written informed consent except cured basal cell carcinoma of skin and cured carcinoma in situ of uterine cervix
- Radiotherapy within 4 weeks after randomization
- History of significant neurologic or psychiatric disorders, and presence or history of CNS metastasis
- Major surgery within 4 weeks before study entry, or insufficient recovery from major surgery (except the patients who received only open and closure or biopsy)
-
Other serious illness or medical conditions as follows;
- Any following conditions occurred within 6 months before study entry: myocardial infarction, severe/unstable angina, bypass surgery for coronary artery/peripheral artery, congestive heart failure (NYHA class III or IV), cerebral infarction or transient ischemic attack
- Conduction abnormality such as 2nd degree or greater AV block or severe arrhythmia that requires medical treatments (right bundle branch block (RBBB) is eligible, but left bundle branch block (LBBB) is not.)
- Uncontrolled hypertension
- Liver cirrhosis (Child Pugh Class B or greater)
- Interstitial pneumonia, pulmonary fibrosis
- Active viral hepatitis B
- Uncontrolled diabetes mellitus
- Uncontrolled ascites or pleural effusion
- Uncontrolled active infection or sepsis
-
Administration of medications which may have potentially pharmacokinetic interaction with S-1, cisplatin, and oxaliplatin
- Flucytosine, a fluorinated pyrimidine antifungal agent
- Anti-viral agents, such as sorivudine, and brivudine, or chemical similar drugs
- Warfarin (except, low dose warfarin for the purpose of prophylaxis), phenprocoumon
- Phenytoin
- Allopurinol
- Participation to other clinical trials or administration of other investigational drugs within 30 days before the randomisation
- Pregnant or lactating women
- Women or men of child bearing potential not employing adequate contraception during study treatments or until the 3 months after the end of study treatments
- Ineligible for the study at the discretion of investigators
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01671449
Korea, Republic of | |
Chungbuk National University Hospital | |
Cheongju-si, Chungcheongbuk-do, Korea, Republic of, 361-711 | |
Seoul National University Bundang Hospital | |
Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707 | |
National Cancer Center | |
Ilsan, Gyeonggi-do, Korea, Republic of | |
Chonnam National University Hwasun Hospital | |
Hwasun-eup, Hwasun-gun, Jeollanam-do, Korea, Republic of, 519-763 | |
Dongnam Institute of Radiological and Medical Sciences | |
Busan, Korea, Republic of, 619-953 | |
Yeungnam University Medical Center | |
Daegu, Korea, Republic of, 705-717 | |
Gangneung Asan Hospital | |
Gangneung-si, Korea, Republic of, 210-711 | |
Seoul St. Mary's hospital of the Catholic University of Korea | |
Seoul, Korea, Republic of, 137-701 | |
Asan Medical Center | |
Seoul, Korea, Republic of, 138-736 |
Principal Investigator: | Min-Hee Ryu, M.D., Ph.D | Asan Medical Center | |
Principal Investigator: | Young-Iee Park, MD., Ph.D. | National Cancer Center, Seoul, Korea | |
Principal Investigator: | Ik-Joo Chung, MD., Ph.D. | Chonnam National University Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Min-Hee Ryu, Asan Medical Center |
ClinicalTrials.gov Identifier: | NCT01671449 |
Other Study ID Numbers: |
AMC-ONCGI-1202 |
First Posted: | August 23, 2012 Key Record Dates |
Last Update Posted: | November 30, 2015 |
Last Verified: | November 2015 |
Gastric cancer S-1 Cisplatin Oxaliplatin |
Stomach Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Stomach Diseases Oxaliplatin Antineoplastic Agents |